北京大学医学部机构知识库
Advanced  
IR@PKUHSC  > 北京大学临床肿瘤学院  > 胃肠肿瘤中心  > 期刊论文
学科主题: 临床医学
题名:
Serum levels of TUBB3 correlate with clinical outcome in Chinese patients with advanced gastric cancer receiving first-line paclitaxel plus capecitabine
作者: Yu, Jingwei; Gao, Jing; Lu, Zhihao; Li, Yilin; Shen, Lin
关键词: Advanced gastric cancer ; Serum ; TUBB3 ; Paclitaxel ; Capecitabine
刊名: MEDICAL ONCOLOGY
发表日期: 2012-12-01
DOI: 10.1007/s12032-012-0292-y
卷: 29, 期:5, 页:3029-3034
收录类别: SCI
文章类型: Article
WOS标题词: Science & Technology
类目[WOS]: Oncology
研究领域[WOS]: Oncology
关键词[WOS]: III BETA-TUBULIN ; PHASE-II ; CHEMOTHERAPY ; EXPRESSION ; CISPLATIN ; TRIAL ; 5-FLUOROURACIL ; METAANALYSIS ; MULTICENTER ; MARKER
英文摘要:

The overexpression of beta-tubulin III (TUBB3) in tumor tissues was reversely related with the efficacy of paclitaxel and clinical outcome in different cancers. In this study, we aimed to investigate the association between serum levels of TUBB3 and clinical outcome in advanced gastric cancer patients receiving first-line paclitaxel plus capecitabine. One hundred and twenty-eight advanced gastric cancer patients receiving first-line paclitaxel plus capecitabine in Peking University Cancer Hospital from December 2006 to October 2010 were enrolled in the study. Serum samples from 32 healthy individuals were used as controls. TUBB3 expression level in advanced gastric cancer was significantly higher than that in healthy control group (31.6 +/- A 17.8 ng/mL vs. 16.9 +/- A 3.8 ng/mL, p < 0.001). For all patients, the clinical benefit rate (CBR), median progression-free survival (PFS), and overall survival (OS) were 55.6 %, 179 and 306 days, respectively. The CBR, median PFS, and OS in patients with low (n = 27) and high levels (n = 101) of TUBB3 were 95.8 %/45.1 % (low vs. high, p < 0.001), 190 days/166 days (p = 0.064), and 360 days/297 days (p = 0.023), respectively. Cox multivariate regression analysis demonstrated that the serum levels of TUBB3 were an independent prognostic factor for advanced gastric cancer patients (HR = 1.950; 95 % CI, 1.242-3.062; p = 0.004). This study indicated that low levels of TUBB3 in serum could predict better response and survival for advanced gastric cancer patients receiving paclitaxel plus capecitabine, which could be used to select patients who would benefit from this regimen.

语种: 英语
所属项目编号: D101100050010023
项目资助者: Beijing Municipal Science &amp ; Technology Commission
WOS记录号: WOS:000311513800004
Citation statistics:
内容类型: 期刊论文
URI标识: http://ir.bjmu.edu.cn/handle/400002259/53035
Appears in Collections:北京大学临床肿瘤学院_胃肠肿瘤中心_期刊论文

Files in This Item:

There are no files associated with this item.


作者单位: Peking Univ Canc Hosp & Inst, Dept Gastrointestinal Oncol, Minist Educ, Key Lab Carcinogenesis & Translat Res, Beijing 100142, Peoples R China

Recommended Citation:
Yu, Jingwei,Gao, Jing,Lu, Zhihao,et al. Serum levels of TUBB3 correlate with clinical outcome in Chinese patients with advanced gastric cancer receiving first-line paclitaxel plus capecitabine[J]. MEDICAL ONCOLOGY,2012,29(5):3029-3034.
Service
Recommend this item
Sava as my favorate item
Show this item's statistics
Export Endnote File
Google Scholar
Similar articles in Google Scholar
[Yu, Jingwei]'s Articles
[Gao, Jing]'s Articles
[Lu, Zhihao]'s Articles
CSDL cross search
Similar articles in CSDL Cross Search
[Yu, Jingwei]‘s Articles
[Gao, Jing]‘s Articles
[Lu, Zhihao]‘s Articles
Related Copyright Policies
Null
Social Bookmarking
Add to CiteULike Add to Connotea Add to Del.icio.us Add to Digg Add to Reddit

Items in IR are protected by copyright, with all rights reserved, unless otherwise indicated.

 

 

Valid XHTML 1.0!
Copyright © 2007-2017  北京大学医学部 - Feedback
Powered by CSpace